“In addition, we are pleased to be bringing ONAPGO to market, another growth driver for our business. ONAPGO represents a novel approach for adults with Parkinson's disease who are experiencing ...

Pipeline assets like Onapgo and potential acquisitions could bolster growth, but uncertainties remain, especially with SPN-820's recent trial failure. I'm downgrading SUPN stock from "Buy" to ...